Clinical trialsCompany release

Aptevo's mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall

🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 16 Nov 2026

Phase 1b RAINIER data show responses in 11 of 14 evaluable TP53-mutated patients, while a refined priming-dose regimen reduced infusion-related reactions, Aptevo said in its Q3 2026 results.

Aptevo Therapeutics reported results for the quarter ended 30 September 2026 in a release dated 16 November 2026, alongside an update on its Phase 1b RAINIER trial of mipletamig in frontline acute myeloid leukaemia (AML).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗

Article written by VigiEye from the official source (Aptevo Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →